Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab and Chemotherapy with Adaptive Re-irradiation in Recurrent NPC
NCT04921995Phase 2Unknown
- Sponsor
- Fudan University
- Start
- Apr 2019
- Primary completion
- Oct 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab in nasopharyngeal carcinoma (NPC), sponsored by Fudan University. Primary endpoints: Objective Response Rate at 3 months and Progression-Free Survival at 2 years. Status: unknown.
02
Drugs
tislelizumab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT04921995.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04921995.